TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-9.4%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$82.9M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$15.1M |
| 2 |
Centene
CNC
|
$8.24M |
| 3 |
Moderna
MRNA
|
$7.61M |
| 4 |
Eli Lilly
LLY
|
$6.73M |
| 5 |
Sanofi
SNY
|
$6.15M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.8M |
| 2 |
Merck
MRK
|
$14.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
$10.3M |
| 4 |
Johnson & Johnson
JNJ
|
$10.2M |
| 5 |
Pfizer
PFE
|
$8.65M |
Sector Composition
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Boston Scientific
BSX
$159B
| $19.2M | 0.87% |
587,662
+23,317
| +4% | +$761K |
|
27
Zoetis
ZTS
$67.9B
| $17.9M | 0.81% |
151,952
-38,432
| -20% | -$4.52M |
|
28
Becton Dickinson
BDX
$55.1B
| $17.9M | 0.81% |
79,698
+11,785
| +17% | +$2.64M |
|
29
Neurocrine Biosciences
NBIX
$14.3B
| $17.8M | 0.81% |
206,150
+13,108
| +7% | +$1.13M |
|
|
30
Centene
CNC
$14.2B
| $17.1M | 0.77% |
288,194
+138,668
| +93% | +$8.24M |
|
31
Intuitive Surgical
ISRG
$167B
| $16.9M | 0.76% |
102,117
-13,932
| -12% | -$2.3M |
|
32
Viatris
VTRS
$12.2B
| $15.1M | 0.68% |
1,010,754
-27,800
| -3% | -$414K |
|
33
Alnylam Pharmaceuticals
ALNY
$59.2B
| $15M | 0.68% |
137,617
-6,178
| -4% | -$672K |
|
34
Elevance Health
ELV
$70.6B
| $14.9M | 0.67% |
65,568
-36,464
| -36% | -$8.28M |
|
35
Novartis
NVS
$251B
| $14.8M | 0.67% |
179,847
-31,200
| -15% | -$2.57M |
|
36
Humana
HUM
$37B
| $14.5M | 0.65% |
46,130
-8,883
| -16% | -$2.79M |
|
|
37
Sanofi
SNY
$113B
| $14.3M | 0.65% |
327,367
+140,727
| +75% | +$6.15M |
|
38
Sarepta Therapeutics
SRPT
$1.96B
| $13.7M | 0.62% |
140,129
-41,494
| -23% | -$4.06M |
|
39
Edwards Lifesciences
EW
$47.5B
| $12.7M | 0.57% |
202,146
-6,525
| -3% | -$410K |
|
40
AstraZeneca
AZN
$253B
| $12.3M | 0.56% |
276,098
| – | – |
|
|
PRAH
41
DELISTED
PRA Health Sciences, Inc.
PRAH
| $11.9M | 0.54% |
143,508
-9,495
| -6% | -$788K |
|
|
HZNP
42
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $11.8M | 0.53% |
399,257
+94,593
| +31% | +$2.8M |
|
43
Bio-Techne
TECH
$8.46B
| $10.9M | 0.49% |
230,764
+30,400
| +15% | +$1.44M |
|
44
Idexx Laboratories
IDXX
$51.4B
| $9.77M | 0.44% |
40,314
-3,300
| -8% | -$799K |
|
45
Acadia Pharmaceuticals
ACAD
$4.26B
| $9.36M | 0.42% |
221,599
+3,316
| +2% | +$140K |
|
46
Welltower
WELL
$112B
| $9.3M | 0.42% |
203,083
+11,437
| +6% | +$524K |
|
|
ONC
47
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $9.23M | 0.42% |
74,984
-6,105
| -8% | -$752K |
|
48
Ionis Pharmaceuticals
IONS
$9.76B
| $9.14M | 0.41% |
193,201
-16,723
| -8% | -$791K |
|
49
IQVIA
IQV
$31.9B
| $8.87M | 0.4% |
82,266
+46,451
| +130% | +$5.01M |
|
50
Exelixis
EXEL
$10.2B
| $8.87M | 0.4% |
515,125
| – | – |
|